Silicon Valley Bank Results Presentation Deck
Continued strong SVB Leerink performance
Expect 2021 SVB Leerink revenue to be between $320M-$360M
SVB Leerink expands our solutions for
life science/healthcare clients
Equity Capital
Markets
Research
Convertibles
BIOPHARMA &
DIAGNOSTICS
svb>
SVBLEERINK
MEDICAL
DEVICES
Ka
M
S
M&A
Expertise
Ju
www.s
Sales &
Go Trading
HEALTHTECH &
HEALTHCARE IT
Alternative
Equities
HEALTHCARE
SERVICES
ā
Q4'20 activity
SVB Leerink continued to capitalize on strong markets (24 bookrun
transactions in Q4, representing over $5.9B in aggregate deal value)
SVB LEERINK REVENUE*
$ Millions
Commissions
Investment
Banking
SVB Leerink
expenses*
73.7
15.5
58.2
62.9
16.0
46.9
158.4
16.9
141.5
108.4
16.2
Q4'19 Q1'20 Q2'20 Q3'20
$75.0M $62.0M $108.7M $77.6M
Investment banking revenue
Normalizing activity in 2021
* Non-GAAP financial measure. See "Use of non-GAAP Financial Measures" in our Q4 2020 Earnings Release and
our non-GAAP reconciliations at the end of this presentation.
92.2
FY'21 outlook key drivers
Shifting conditions may create volatility for market sensitive revenues:
Commissions revenue
Sales and trading may benefit from market volatility
Strengthening collaboration
Between Silicon Valley Bank and SVB Leerink
150.9
17.4
133.4
Q4'20
$130.7M
Q4 2020 Financial Highlights
28View entire presentation